Neurocrine Biosciences (NBIX) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and Neurocrine Biosciences published the results on November 2, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison. Neurocrine Biosciences reports EPS two ways: GAAP, under the accounting rules every US filer follows, and non-GAAP, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• Neurocrine completed its acquisition of Soleno Therapeutics, which markets VYKAT XR, on May 18, 2026. VYKAT XR sales and amortization of the acquired intangible assets were not in the year-ago quarter.
• Other revenues are mainly royalties on AbbVie's elagolix and Tanabe Pharma's valbenazine sales. The year-ago figure also included product sales of Neurocrine Group Limited, which was sold on January 21, 2026.

Source: Neurocrine Biosciences Q3 2026 results, November 2, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Neurocrine Biosciences splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Neurocrine Biosciences's INGREZZA revenue was $802 million in Q3 2026, up 17% from $687 million in Q3 2025, 71% of total revenue.
• Neurocrine Biosciences's CRENESSITY revenue was $211 million in Q3 2026, up 115% from $98.1 million in Q3 2025, 19% of total revenue.
• Neurocrine Biosciences's VYKAT XR revenue was $107 million in Q3 2026, 10% of total revenue.
• Neurocrine Biosciences's Other revenues revenue was $3.7 million in Q3 2026, down 64% from $10.2 million in Q3 2025, under 1% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

The release's guidance table also lowers GAAP SG&A to $1,540 million to $1,560 million (from $1,575 million to $1,600 million) and non-GAAP SG&A to $1,290 million to $1,310 million, and leaves GAAP R&D at $1,275 million to $1,325 million.

In its Q3 2026 release, Neurocrine Biosciences said:

“INGREZZA full year 2026 guidance was increased from a range of $2.825 billion to $2.875 billion up to $2.9 billion to $2.925 billion.”

“R&D guidance reflects the continued advancement of the Company's pre-clinical and clinical portfolio including the Phase 3 programs for osavampator in major depressive disorder and direclidine in schizophrenia, and includes approximately $33 million of expense for development milestones related to our in-licensed product candidates.”

Source: Neurocrine Biosciences Q3 2026 release, Nov 2, 2026.

This is the company's own guidance as of Nov 2, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the NBIX forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP total revenues and diluted EPS, each as first reported in that quarter's release.

We do not hold a confirmed date for Neurocrine Biosciences's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Nov 2, 2026

Neurocrine Biosciences earns almost all of its revenue from three marketed drugs. In Q3 2026 INGREZZA (valbenazine), for tardive dyskinesia and chorea associated with Huntington's disease, brought in $801.5 million of the $1,122.7 million total. CRENESSITY (crinecerfont), for classic congenital adrenal hyperplasia, added $210.8 million and VYKAT XR (diazoxide choline), for hyperphagia in Prader-Willi syndrome, $106.7 million. Net product sales passed $1 billion in a quarter for the first time. (Neurocrine Biosciences Q3 2026 release, Nov 2, 2026; Neurocrine Biosciences Form 10-Q, Q3 2026, Nov 2, 2026)

Neurocrine said INGREZZA's 17% rise came from double-digit volume growth, with record total and new prescriptions and high persistency. CRENESSITY, launched in December 2024, more than doubled from $98.1 million, on steady new patient demand with approximately 80% reimbursement for dispensed prescriptions. (Neurocrine Biosciences Q3 2026 release, Nov 2, 2026; Neurocrine Biosciences Form 10-Q, Q3 2026, Nov 2, 2026)

VYKAT XR came with Neurocrine's purchase of Soleno Therapeutics, completed on May 18, 2026 in an all-cash deal with a total equity value of approximately $2.9 billion. Neurocrine recorded approximately $2.2 billion of VYKAT XR intellectual property, amortized over 16 years, and approximately $168 million of inventory fair value step-up. (Neurocrine Biosciences Form 10-Q, Q3 2026, Nov 2, 2026; Neurocrine Biosciences Q3 2026 release, Nov 2, 2026)

Neurocrine's product sales are concentrated in a few customers. Over the first nine months of 2026 three customers accounted for 36%, 24% and 29% of gross product sales, and the largest held 48% of accounts receivable at September 30, 2026. Collaboration revenues, mainly royalties on AbbVie's elagolix and Tanabe Pharma's valbenazine sales, were $3.7 million. (Neurocrine Biosciences Form 10-Q, Q3 2026, Nov 2, 2026)

Neurocrine's GAAP diluted EPS fell to $1.96 from $2.04 even as revenue grew 41%, while non-GAAP EPS rose to $3.29 from $2.17. The non-GAAP figure excludes stock-based compensation of $54.3 million, amortization of acquired intangible assets of $35.0 million, a $52.3 million loss on equity investments, $16.7 million of acquisition-related compensation and severance, and $6.3 million of inventory step-up amortization, less a $28.2 million tax effect. (Neurocrine Biosciences Q3 2026 release, Nov 2, 2026)

Spending at Neurocrine grew with the portfolio. GAAP R&D rose to $351.8 million from $250.0 million, including investment in the Phase 3 programs for osavampator in major depressive disorder and direclidine in schizophrenia, and GAAP SG&A rose to $366.3 million from $291.6 million after sales force expansion and the VYKAT XR launch. Acquired in-process R&D was $11.7 million. (Neurocrine Biosciences Q3 2026 release, Nov 2, 2026)

Neurocrine's effective tax rate was 27.2%, against 28.2% a year earlier. Diluted weighted average shares rose to 105.2 million from 102.5 million. It repurchased 0.6 million shares for $92.1 million in the quarter, leaving $174.2 million under its 2025 program, and its cash, cash equivalents and marketable securities fell to approximately $790 million from $2,543 million at the end of 2025 after the Soleno purchase. (Neurocrine Biosciences Q3 2026 release, Nov 2, 2026; Neurocrine Biosciences Form 10-Q, Q3 2026, Nov 2, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Neurocrine guides only INGREZZA sales and operating expenses, not total revenue or EPS. In the Q3 2026 release it raised full-year INGREZZA net product sales guidance to $2.9 billion to $2.925 billion from $2.825 billion to $2.875 billion, lowered GAAP SG&A to $1,540 million to $1,560 million and kept GAAP R&D at $1,275 million to $1,325 million. (Neurocrine Biosciences Q3 2026 release, Nov 2, 2026)

Through the first nine months of 2026 INGREZZA sales were $2,174.8 million, so the new range implies fourth-quarter INGREZZA sales of roughly $725 million to $750 million. Neurocrine gives no guidance for CRENESSITY or VYKAT XR and plans an R&D Day on December 15, 2026. (Neurocrine Biosciences Form 10-Q, Q3 2026, Nov 2, 2026; Neurocrine Biosciences Q3 2026 release, Nov 2, 2026)

A consensus figure is the average of the models published by the analysts who cover Neurocrine Biosciences, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Neurocrine Biosciences's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning NBIX is on is NBIX a buy or a sell?, what analysts expect next is on the NBIX forecast, and what the company does is on the Neurocrine Biosciences (NBIX) stock page.

Every number on this page can be traced to a document Neurocrine Biosciences published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.